07:00 , Oct 29, 2015 |  BC Innovations  |  Product R&D

Qureing antibiotic resistance

QureTech Bio AB is targeting chlamydia and tuberculosis with compounds that disable, rather than kill, pathogens to circumvent antibiotic resistance. By targeting the organisms' virulence factors, the company hopes to spare the host flora and...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Clinical News

MEDI3902 regulatory update

AstraZeneca's MedImmune LLC unit said FDA granted Fast Track designation to MEDI3902 to prevent nosocomial pneumonia caused by Pseudomonas aeruginosa. MedImmune said MEDI3902 is entering Phase I trials. The bispecific mAb targets P. aeruginosa type...